{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-262795","form_type":"8-K","ticker":"SLDB","cik":"0001707502","company_name":"Solid Biosciences Inc.","filed_at":"2025-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.221401+00:00","generated_at":"2026-05-17T00:54:39.421600+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Solid Biosciences Q3 cash $236.1M; INSPIRE DUCHENNE shows 58% microdystrophin expression, strong biomarker correlations","bullets":["Cash, cash equivalents and available-for-sale securities: $236.1M as of Sep 30, 2025; runway into H1 2027.","Interim INSPIRE DUCHENNE data (N=10 at Day 90): mean microdystrophin expression 58% by western blot and mass spectrometry, positive fibers 51%.","Statistical correlations (Pearson r=0.95) between microdystrophin and beta-sarcoglycan/nNOS restoration; r=-0.78 for CK reduction at Day 180.","Safety: SGT-003 generally well tolerated with steroid-only prophylaxis; one Grade 3 myositis SAE resolved; no DILI; asymptomatic platelet declines ameliorated.","Regulatory: FDA meeting planned H1 2026 to discuss accelerated approval; Phase 3 IMPACT DUCHENNE initiated ex-US; SGT-212 and SGT-501 trials activated."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-262795","json":"https://secwatch.observer/filing/0001193125-25-262795.json","markdown":"https://secwatch.observer/filing/0001193125-25-262795.md","text":"https://secwatch.observer/filing/0001193125-25-262795.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1707502/000119312525262795/0001193125-25-262795-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1707502/000119312525262795/d87050d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:54:39.421600+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}